Ameriprise Financial Inc. grew its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 7.0% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 126,803 shares of the biotechnology company’s stock after buying an additional 8,347 shares during the period. Ameriprise Financial Inc. owned 0.87% of Anika Therapeutics worth $6,257,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Anika Therapeutics by 6.6% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,423,593 shares of the biotechnology company’s stock valued at $70,241,000 after buying an additional 88,418 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Anika Therapeutics by 5.5% in the first quarter. Dimensional Fund Advisors LP now owns 771,699 shares of the biotechnology company’s stock valued at $33,522,000 after buying an additional 40,020 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Anika Therapeutics by 76.8% in the second quarter. Bank of New York Mellon Corp now owns 490,433 shares of the biotechnology company’s stock valued at $24,199,000 after buying an additional 213,055 shares during the last quarter. State Street Corp raised its holdings in shares of Anika Therapeutics by 10.3% in the first quarter. State Street Corp now owns 349,292 shares of the biotechnology company’s stock valued at $15,171,000 after buying an additional 32,501 shares during the last quarter. Finally, AMI Asset Management Corp raised its holdings in shares of Anika Therapeutics by 23.0% in the second quarter. AMI Asset Management Corp now owns 309,059 shares of the biotechnology company’s stock valued at $15,249,000 after buying an additional 57,797 shares during the last quarter. 84.32% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/ameriprise-financial-inc-increases-stake-in-anika-therapeutics-inc-anik/1642596.html.

Anika Therapeutics Inc. (NASDAQ ANIK) opened at 59.75 on Friday. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $60.27. The stock has a market capitalization of $875.82 million, a PE ratio of 26.54 and a beta of 1.66. The company’s 50-day moving average is $57.37 and its 200 day moving average is $50.18.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The business had revenue of $33.50 million during the quarter, compared to analyst estimates of $27.20 million. During the same period in the previous year, the business posted $0.57 EPS. The company’s quarterly revenue was up 25.9% on a year-over-year basis. On average, analysts predict that Anika Therapeutics Inc. will post $2.20 EPS for the current year.

Several research analysts recently issued reports on ANIK shares. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th. Zacks Investment Research raised shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd.

In related news, CEO Charles H. Sherwood sold 3,293 shares of Anika Therapeutics stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $60.04, for a total value of $197,711.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Charles H. Sherwood sold 7,124 shares of Anika Therapeutics stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $60.08, for a total transaction of $428,009.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 74,216 shares of company stock worth $3,866,073. 6.57% of the stock is currently owned by insiders.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.